Literature DB >> 22432059

Predicting success or failure of immunotherapy for cancer: insights from a clinically applicable mathematical model.

Charles F Babbs1.   

Abstract

The objective of this study was to create a clinically applicable mathematical model of immunotherapy for cancer and use it to explore differences between successful and unsuccessful treatment scenarios. The simplified predator-prey model includes four lumped parameters: tumor growth rate, g; immune cell killing efficiency, k; immune cell signaling factor, λ; and immune cell half-life decay, μ. The predator-prey equations as functions of time, t, for normalized tumor cell numbers, y, (the prey) and immunocyte numbers, ×, (the predators) are: dy/dt = gy - kx and dx/dt = λxy - μx. A parameter estimation procedure that capitalizes on available clinical data and the timing of clinically observable phenomena gives mid-range benchmarks for parameters representing the unstable equilibrium case in which the tumor neither grows nor shrinks. Departure from this equilibrium results in oscillations in tumor cell numbers and in many cases complete elimination of the tumor. Several paradoxical phenomena are predicted, including increasing tumor cell numbers prior to a population crash, apparent cure with late recurrence, one or more cycles of tumor growth prior to eventual tumor elimination, and improved tumor killing with initially weaker immune parameters or smaller initial populations of immune cells. The model and the parameter estimation techniques are easily adapted to various human cancers that evoke an immune response. They may help clinicians understand and predict certain strange and unexpected effects in the world of tumor immunity and lead to the design of clinical trials to test improved treatment protocols for patients.

Entities:  

Keywords:  Adoptive; Lotka-Volterra; basal cell carcinoma; imiquimod; immune modulation; lymphoma; melanoma; predator-prey; tumor infiltrating lymphocytes

Year:  2012        PMID: 22432059      PMCID: PMC3304570     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  29 in total

1.  Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon.

Authors:  Jacques Banchereau; Hideki Ueno; Madhav Dhodapkar; John Connolly; Jennifer P Finholt; Eynav Klechevsky; Jean-Philippe Blanck; Dennis A Johnston; A Karolina Palucka; Joseph Fay
Journal:  J Immunother       Date:  2005 Sep-Oct       Impact factor: 4.456

2.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

Review 3.  Review of interleukin-2 alone and interleukin-2/LAK clinical trials in metastatic malignant melanoma.

Authors:  M Sznol; J P Dutcher; M B Atkins; A R Rayner; K A Margolin; E R Gaynor; G R Weiss; F Aronson; D R Parkinson; M J Hawkins
Journal:  Cancer Treat Rev       Date:  1989-06       Impact factor: 12.111

4.  Comparing interferon- gamma release assay with tuberculin skin test readings at 48-72 hours and 144-168 hours with use of 2 commercial reagents.

Authors:  David Tat; Hari Polenakovik; Thomas Herchline
Journal:  Clin Infect Dis       Date:  2004-12-17       Impact factor: 9.079

Review 5.  Immunology and disease control: a systems approach.

Authors:  A L Asachenkov; G I Marchuk; R R Mohler; S M Zuev
Journal:  IEEE Trans Biomed Eng       Date:  1994-10       Impact factor: 4.538

Review 6.  White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.

Authors:  Jeffrey Weber; Michael Atkins; Patrick Hwu; Laszlo Radvanyi; Mario Sznol; Cassian Yee
Journal:  Clin Cancer Res       Date:  2011-02-15       Impact factor: 12.531

7.  Modeling immunotherapy of the tumor-immune interaction.

Authors:  D Kirschner; J C Panetta
Journal:  J Math Biol       Date:  1998-09       Impact factor: 2.259

Review 8.  Next generation of immunotherapy for melanoma.

Authors:  John M Kirkwood; Ahmad A Tarhini; Monica C Panelli; Stergios J Moschos; Hassane M Zarour; Lisa H Butterfield; Helen J Gogas
Journal:  J Clin Oncol       Date:  2008-07-10       Impact factor: 44.544

9.  Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model.

Authors:  Satoshi Wada; Kiyoshi Yoshimura; Edward L Hipkiss; Tim J Harris; Hung-Rong Yen; Monica V Goldberg; Joseph F Grosso; Derese Getnet; Angelo M Demarzo; George J Netto; Robert Anders; Drew M Pardoll; Charles G Drake
Journal:  Cancer Res       Date:  2009-05-12       Impact factor: 12.701

Review 10.  Betting on immunotherapy for melanoma.

Authors:  Mario Sznol
Journal:  Curr Oncol Rep       Date:  2009-09       Impact factor: 5.075

View more
  8 in total

Review 1.  A review of quantitative modeling of B cell responses to antigenic challenge.

Authors:  Timothy P Hickling; Xiaoying Chen; Paolo Vicini; Satyaprakash Nayak
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-10-19       Impact factor: 2.745

2.  How many neutrophils are enough (redux, redux)?

Authors:  Samuel C Silverstein; Raul Rabadan
Journal:  J Clin Invest       Date:  2012-07-23       Impact factor: 14.808

3.  A biased competition theory of cytotoxic T lymphocyte interaction with tumor nodules.

Authors:  Claire Christophe; Sabina Müller; Magda Rodrigues; Anne-Elisabeth Petit; Patrick Cattiaux; Loïc Dupré; Sébastien Gadat; Salvatore Valitutti
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

4.  On Study of Immune Response to Tumor Cells in Prey-Predator System.

Authors:  Gurpreet Kaur; Naseem Ahmad
Journal:  Int Sch Res Notices       Date:  2014-09-22

5.  Shortwave infrared emitting multicolored nanoprobes for biomarker-specific cancer imaging in vivo.

Authors:  Harini Kantamneni; Shravani Barkund; Michael Donzanti; Daniel Martin; Xinyu Zhao; Shuqing He; Richard E Riman; Mei Chee Tan; Mark C Pierce; Charles M Roth; Vidya Ganapathy; Prabhas V Moghe
Journal:  BMC Cancer       Date:  2020-11-10       Impact factor: 4.430

6.  Immunosuppressive niche engineering at the onset of human colorectal cancer.

Authors:  Chandler D Gatenbee; Ann-Marie Baker; Ryan O Schenck; Maximilian Strobl; Jeffrey West; Margarida P Neves; Sara Yakub Hasan; Eszter Lakatos; Pierre Martinez; William C H Cross; Marnix Jansen; Manuel Rodriguez-Justo; Christopher J Whelan; Andrea Sottoriva; Simon Leedham; Mark Robertson-Tessi; Trevor A Graham; Alexander R A Anderson
Journal:  Nat Commun       Date:  2022-04-04       Impact factor: 14.919

7.  Insights From the Ecology of Information to Cancer Control.

Authors:  Christopher J Whelan; Stanislav S Avdieiev; Robert A Gatenby
Journal:  Cancer Control       Date:  2020 Jul-Aug       Impact factor: 3.302

8.  Dynamic Phenotypic Switching and Group Behavior Help Non-Small Cell Lung Cancer Cells Evade Chemotherapy.

Authors:  Arin Nam; Atish Mohanty; Supriyo Bhattacharya; Sourabh Kotnala; Srisairam Achuthan; Kishore Hari; Saumya Srivastava; Linlin Guo; Anusha Nathan; Rishov Chatterjee; Maneesh Jain; Mohd W Nasser; Surinder Kumar Batra; Govindan Rangarajan; Erminia Massarelli; Herbert Levine; Mohit Kumar Jolly; Prakash Kulkarni; Ravi Salgia
Journal:  Biomolecules       Date:  2021-12-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.